Matches in SemOpenAlex for { <https://semopenalex.org/work/W1916907730> ?p ?o ?g. }
- W1916907730 abstract "Background A blood transfusion is an acute intervention, implemented to solve life and health‐threatening conditions on a short‐term basis. However, blood transfusions have adverse events, some of them potentially related to immune modulation or to a direct transmission of infectious agents (e.g. cytomegalovirus). Leukoreduction is a process in which the white blood cells are intentionally reduced in packed red blood cells (PRBCs) in order to reduce the risk of adverse reactions. The potential benefits of leukoreduced PRBCs in all types of transfused patients for decreasing infectious and non‐infectious complications remain unclear. Objectives To determine the clinical effectiveness of leukoreduction of packed red blood cells for preventing adverse reactions following allogeneic blood transfusion. Search methods We ran the most recent search on 10th November 2015. We searched the Cochrane Injuries Group's Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library), MEDLINE (OvidSP), Embase(OvidSP), CINAHL Plus (EBSCO), LILACS (BIREME), and clinical trials registers. In addition, we checked the reference lists of all relevant trials and reviews identified in the literature searches. Selection criteria Randomised clinical trials including patients of all ages requiring PRBC allogeneic transfusion. Any study was eligible for inclusion, regardless of the length of participant follow‐up or country where the study was performed. The primary outcome was transfusion‐related acute lung injury (TRALI). Secondary outcomes were death from any cause, infection from any cause, non‐infectious complications and any other adverse event. Data collection and analysis At least two review authors independently performed study selection, 'Risk of bias' assessments and data extraction. We estimated pooled relative risk for dichotomous outcomes, and we measured statistical heterogeneity using I² statistic. The random‐effects model was used to synthesise results. We conducted a trial sequential analysis to assess the risk of random errors in cumulative meta‐analyses. Main results Thirteen studies, most including adult patients, met the eligibility criteria. We found no clear evidence of an effect of leukoreduced PRBC versus non‐leukoreduced PRBC in patients that were randomised to receive transfusion for the following outcomes: TRALI: RR 0.96, 95% CI 0.67 to 1.36, P = 0.80 from one trial reporting data on 1864 trauma patients. The accrued information of 1864 participants constituted only 28.5% of the diversity‐adjusted required information size (DARIS) of 6548 participants. The quality of evidence was low. Death from any cause: RR 0.81, 95% CI 0.58 to 1.12, I² statistic = 63%, P = 0.20 from nine trials reporting data on 6485 cardiovascular surgical patients, gastro‐oncology surgical patients, trauma patients and HIV infected patients. The accrued information of 6485 participants constituted only 55.3% of the DARIS of 11,735 participants. The quality of evidence was very low. Infection from any cause: RR 0.80, 95% CI 0.62 to 1.03, I² statistic = 84%, P = 0.08 from 10 trials reporting data on 6709 cardiovascular surgical patients, gastro‐oncology surgical patients, trauma patients and HIV infected patients. The accrued information of 6709 participants constituted only 60.6% of the DARIS of 11,062 participants. The quality of evidence was very low. Adverse events: The only adverse event reported as an adverse event was fever (RR 0.81, 95% CI 0.64 to 1.02; I² statistic= 0%, P = 0.07). Fever was reported in two trials on 634 cardiovascular surgical and gastro‐oncology surgical patients. The accrued information of 634 participants constituted only 84.4% of the DARIS of 751 participants. The quality of evidence was low. Incidence of other non‐infectious complications: This outcome was not assessed in any included trial. Authors' conclusions There is no clear evidence for supporting or rejecting the routine use of leukoreduction in all patients requiring PRBC transfusion for preventing TRALI, death, infection, non‐infectious complications and other adverse events. As the quality of evidence is very low to low, more evidence is needed before a definitive conclusion can be drawn." @default.
- W1916907730 created "2016-06-24" @default.
- W1916907730 creator A5031725878 @default.
- W1916907730 creator A5049696539 @default.
- W1916907730 creator A5051753481 @default.
- W1916907730 creator A5054278670 @default.
- W1916907730 date "2015-12-03" @default.
- W1916907730 modified "2023-10-03" @default.
- W1916907730 title "Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion" @default.
- W1916907730 cites W1025463489 @default.
- W1916907730 cites W12253643 @default.
- W1916907730 cites W1501448036 @default.
- W1916907730 cites W1505181428 @default.
- W1916907730 cites W1547687869 @default.
- W1916907730 cites W1565676850 @default.
- W1916907730 cites W1568795580 @default.
- W1916907730 cites W1574774469 @default.
- W1916907730 cites W1577750289 @default.
- W1916907730 cites W1637179763 @default.
- W1916907730 cites W1800397150 @default.
- W1916907730 cites W1964650799 @default.
- W1916907730 cites W1966643425 @default.
- W1916907730 cites W1971441597 @default.
- W1916907730 cites W1975082550 @default.
- W1916907730 cites W1975101256 @default.
- W1916907730 cites W1980829041 @default.
- W1916907730 cites W1981680557 @default.
- W1916907730 cites W1982435133 @default.
- W1916907730 cites W1984253491 @default.
- W1916907730 cites W1991084454 @default.
- W1916907730 cites W1993546125 @default.
- W1916907730 cites W1995220443 @default.
- W1916907730 cites W1996634816 @default.
- W1916907730 cites W1997797839 @default.
- W1916907730 cites W1998508664 @default.
- W1916907730 cites W1999415288 @default.
- W1916907730 cites W2000641367 @default.
- W1916907730 cites W2003756366 @default.
- W1916907730 cites W2006115390 @default.
- W1916907730 cites W2006569302 @default.
- W1916907730 cites W2007056023 @default.
- W1916907730 cites W2009326492 @default.
- W1916907730 cites W2010149513 @default.
- W1916907730 cites W2011153220 @default.
- W1916907730 cites W2012149199 @default.
- W1916907730 cites W2022134952 @default.
- W1916907730 cites W2022857671 @default.
- W1916907730 cites W2027216244 @default.
- W1916907730 cites W2028722252 @default.
- W1916907730 cites W2034189468 @default.
- W1916907730 cites W2045786699 @default.
- W1916907730 cites W2050985964 @default.
- W1916907730 cites W2057237518 @default.
- W1916907730 cites W2062828837 @default.
- W1916907730 cites W2066530848 @default.
- W1916907730 cites W2071688599 @default.
- W1916907730 cites W2078736533 @default.
- W1916907730 cites W2079535809 @default.
- W1916907730 cites W2080616464 @default.
- W1916907730 cites W2083564303 @default.
- W1916907730 cites W2090132603 @default.
- W1916907730 cites W2090142570 @default.
- W1916907730 cites W2093043874 @default.
- W1916907730 cites W2096838691 @default.
- W1916907730 cites W2097517425 @default.
- W1916907730 cites W2100222319 @default.
- W1916907730 cites W2100553606 @default.
- W1916907730 cites W2104109275 @default.
- W1916907730 cites W2104675861 @default.
- W1916907730 cites W2107664828 @default.
- W1916907730 cites W2108696783 @default.
- W1916907730 cites W2109346853 @default.
- W1916907730 cites W2111006543 @default.
- W1916907730 cites W2111560082 @default.
- W1916907730 cites W2113782980 @default.
- W1916907730 cites W2114915301 @default.
- W1916907730 cites W2117425158 @default.
- W1916907730 cites W2118713056 @default.
- W1916907730 cites W2119463649 @default.
- W1916907730 cites W2124215468 @default.
- W1916907730 cites W2125435699 @default.
- W1916907730 cites W2127407097 @default.
- W1916907730 cites W2127877465 @default.
- W1916907730 cites W2128587503 @default.
- W1916907730 cites W2129768718 @default.
- W1916907730 cites W2130747536 @default.
- W1916907730 cites W2135400982 @default.
- W1916907730 cites W2137030073 @default.
- W1916907730 cites W2138577499 @default.
- W1916907730 cites W2139390001 @default.
- W1916907730 cites W2144978857 @default.
- W1916907730 cites W2146325711 @default.
- W1916907730 cites W2147581466 @default.
- W1916907730 cites W2148621382 @default.
- W1916907730 cites W2150583859 @default.
- W1916907730 cites W2157561195 @default.
- W1916907730 cites W2160878167 @default.
- W1916907730 cites W2163332984 @default.
- W1916907730 cites W2165224344 @default.
- W1916907730 cites W2165626995 @default.